Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy

Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy

Objectives: Evaluation of the feasibility of SARS-CoV-2-specific T cell manufacturing for adoptive T cell transfer in COVID-19 patients at risk to develop severe disease. Methods: Antiviral SARS-CoV-2-specific T cells were detected in blood of convalescent COVID-19 patients following stimulation wit...

Full description

Bibliographic Details
Main Authors: Barnstorf-Brandes, J. (Author), Baurmann, H. (Author), Blasczyk, R. (Author), Bonifacius, A. (Author), Brauns, O. (Author), Clark, C. (Author), Cornely, O.A (Author), Eiz-Vesper, B. (Author), Gödecke, N. (Author), Goudeva, L. (Author), Hallek, M. (Author), Koch, S. (Author), Köhler, P. (Author), Lang, P. (Author), Maecker-Kolhoff, B. (Author), Martens, J. (Author), Mausberg, P. (Author), Santamorena, M.M (Author), Schenk, J. (Author), Seiferling, D. (Author), Simon, M. (Author), Tischer-Zimmermann, S. (Author), Verboom, M. (Author), Wittig, J. (Author)
Format: Article
Language:English
Published: Frontiers Media S.A. 2022
Subjects:
Activation analysis
adoptive T cell therapy
Adoptive T cell therapy
Antiviral T cell
antiviral T cells
Antivirals
Blood
Cell products
Cell therapy
Cell/B.E
COVID-19
Cytology
Cytotoxic
Diagnosis
Diseases
immunotherapy
Immunotherapy
Manufacture
Polymerase chain reaction
SARS
SARS-CoV-2
T-cells
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items